Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Michalis Karamouzis"'
Autor:
Dimitra Galiti, Helena Linardou, Sofia Agelaki, Athanasios Karampeazis, Nikolaos Tsoukalas, Amanda Psyrri, Michalis Karamouzis, Konstantinos N. Syrigos, Alexandros Ardavanis, Ilias Athanasiadis, Eleni Arvanitou, Stavroula Sgourou, Anastasia Mala, Christos Vallilas, Ioannis Boukovinas
Publikováno v:
Current Oncology, Vol 30, Iss 8, Pp 7608-7619 (2023)
Introduction: The increasing burden of cancer, the development of novel therapies, and the COVID-19 pandemic have made cancer care more complex. Digital innovation was then pushed toward developing platforms to facilitate access to cancer care. Age,
Externí odkaz:
https://doaj.org/article/00acd5ac1cd74c8bb41c30f3c9c61714
Autor:
Ioannis Sougklakos, Elias Athanasiadis, Ioannis Boukovinas, Michalis Karamouzis, Aggelos Koutras, Paulos Papakotoulas, Dimitra Latsou, Magda Hatzikou, Eugena Stamuli, Athanasios Balasopoulos, Aggelos Sideris
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 20, Iss 1, Pp 1-10 (2022)
Abstract Objectives Colorectal cancer (CRC) is the second leading cause of cancer in Europe, with 1.931.590 people newly diagnosed in 2020. The purpose of this study is the investigation of treatment options and healthcare resource metastatic CRC (mC
Externí odkaz:
https://doaj.org/article/6b879deba875439bb29d3d0ec913a78f
Autor:
Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouzis
Publikováno v:
Biomedicines, Vol 11, Iss 5, p 1267 (2023)
Background: Trifluridine/tipiracil (FTD/TPI) is an oral antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue that inhibits cell proliferation following its incorporation into DNA, and tipiracil that helps maintain the
Externí odkaz:
https://doaj.org/article/127365e0afa7497098993b8317173877
Autor:
Michalis Karamouzis, Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Pavlos Papakotoulas, Alexandros Bokas, Dimitrios Schizas, Alexandros Papalampros, Evangelos Felekouras, Theodoros Liakakos, Athanasios Papavassiliou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/c676cd14f2ca4d55990d33110f1bc142
Autor:
Dimitrios Matthaios, Maria Tolia, Davide Mauri, Konstantinos Kamposioras, Michalis Karamouzis
Publikováno v:
Biomedicines, Vol 9, Iss 12, p 1949 (2021)
Hippo pathway with its main molecule YAP is a crucial pathway for development, tissue homeostasis, wound healing, tissue regeneration, and cancer. In this review, we discuss the multiple effects of the YAP/Hippo pathway in the immune system and cance
Externí odkaz:
https://doaj.org/article/12ce23a739624eb18950a2692f75c9f1
Autor:
Dimitra Galiti, Helena Linardou, Sofia Agelaki, Athanasios Karampeazis, Nikolaos Tsoukalas, Amanda Psyrri, Michalis Karamouzis, Konstantinos Syrigos, Alexandros Ardavanis, Ilias Athanasiadis, Eleni Arvanitou, Stavroula Sgourou, Vasileios Kouloulias, Anastasia Mala, Christos Vallilas, Ioannis Boukovinas
Background: Globally 43.8 million people live with cancer. A 60% increase of cancer cases is estimated by 2040, with 29.4 million patients per year requiring therapy. Optimization of cancer management, using digital innovation, is urgently needed. Cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bca1b7ed7d2918d13a4ed2c45db0a356
https://doi.org/10.21203/rs.3.rs-1015730/v1
https://doi.org/10.21203/rs.3.rs-1015730/v1
Autor:
Ozan Yazici, Gokhan Ucar, Osman Sütcüoglu, Nazım Serdar Turhal, Birol Yildiz, Michalis Karamouzis, Sinan Yavuz, Nuri Karadurmuş, Nurullah Zengin, Ravit Geva, Huseyin Abali
Publikováno v:
Current medical research and opinion. 38(4)
Objective The successful results obtained in trials may not necessarily translate into prolonged survival of metastatic colorectal cancer (mCRC) patients in real life. This multinational registry study aimed to evaluate the real-life data effecting t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3353cac9542ada893cf8582616b38d85
https://pubmed.ncbi.nlm.nih.gov/35112975
https://pubmed.ncbi.nlm.nih.gov/35112975
Autor:
Yelena Y. Janjigian, Kohei Shitara, Markus H. Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, Arinilda Silva Campos Bragagnoli, Tianshu Liu, Mustapha Tehfe, Elena Elimova, Ricardo Elias Bruges Maya, James M. Cleary, Michalis Karamouzis, Samira Soleymani, Ming Lei, Carlos Amaya-Chanaga, Jaffer A. Ajani
Publikováno v:
Journal of Clinical Oncology. 41:291-291
291 Background: NIVO + chemo demonstrated superior overall survival (OS) and clinically meaningful progression-free survival (PFS) benefit vs chemo and an acceptable safety profile in previously untreated patients (pts) with advanced GC/GEJC/EAC, lea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b1e00341b23ce91ce3a594743a3ee5a
https://doi.org/10.1200/jco.2023.41.4_suppl.291
https://doi.org/10.1200/jco.2023.41.4_suppl.291
Autor:
Olga Gouli, George Dadous, Michalis Karamouzis, Pavlos C. Papadopoulos, Ioannis Kanonidis, P. Kotridis, Basile Kokkas, C.L. Papadopoulos, G. Sakadamis, Chrisoula Karantona, Joshef Karadoumanis
Publikováno v:
Blood Pressure. 11:91-94
The aim of this study was to evaluate the medium-term effects of the selective AT 1 -blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c72166ab421bf1d43a060df92e4c5783
https://doi.org/10.1080/08037050211263
https://doi.org/10.1080/08037050211263